How often can I take Wegovy, and what decides the schedule?

Why once a week, and can you take it more often?

The straightforward answer is no, Wegovy cannot safely be taken more often than once every seven days. Semaglutide has a half-life of approximately one week, which is precisely why the weekly dosing interval exists. Taking a second dose before that seven-day window closes does not accelerate results; it stacks the medicine in your system and raises the likelihood of nausea, vomiting, and other gastrointestinal effects considerably. The NHS semaglutide medicines page is clear that the dose is once weekly and that patients should not take an extra dose to make up for one that was missed or forgotten.

There is some flexibility in which day you inject, and many people find it helpful to anchor the injection to something predictable, first thing Monday morning, or a Sunday evening ritual. If you ever need to shift your regular day (travelling over the usual day, for example), the minimum gap between two consecutive doses is five days rather than seven. Any change to your schedule is worth discussing with your prescriber first, since they can flag whether it interacts with anything else in your plan.

One practical note: if payday, a bank holiday, or a stretch away from home means you are thinking about your next supply, build that lead time in. Orders placed with an online pharmacy before midday on a working day are dispatched the same afternoon, so a Monday order has a very different timeline to a Friday one.

The titration schedule: how the dose changes over time

The reason the dosing frequency stays constant while the amount changes is that the titration ladder is designed to let your body adapt gradually. Treatment starts at 0.25 mg, a dose chosen primarily to minimise early side effects rather than to drive significant weight loss. After roughly four weeks, a prescriber typically steps this up to 0.5 mg, then 1.0 mg, then 1.7 mg, before reaching the 2.4 mg maintenance dose. The newer 7.2 mg pen, approved by the MHRA in April 2026, follows the same principle: it begins at 0.25 mg and reaches 7.2 mg via the same gradual ladder.

Throughout all of this, the weekly frequency never changes. What changes is purely the strength. Your prescriber will not move you to a higher rung until they are satisfied you are tolerating the current one, which is why clinical review before each dose increase matters. At nume, that review happens before any repeat supply is dispatched. If you are curious whether Wegovy might be suitable for you specifically, that question belongs in a consultation rather than a product page.

It is also worth knowing that the titration schedule cannot be compressed. Spending less than four weeks at each step is not simply a shortcut to the maintenance dose; it is associated with a sharper rise in GI side effects and is outside the licensed guidance. Patience with the schedule is built into the medicine's design.

What the eligibility criteria say about who follows this schedule

The licensed indication for Wegovy covers adults with a BMI of 30 or above, or 27 or above where at least one weight-related condition is present, hypertension, dyslipidaemia, type 2 diabetes, obstructive sleep apnoea, and cardiovascular disease are the conditions most commonly cited. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. A full picture of the eligibility criteria for Wegovy covers these in more detail.

What is important for dosing is that eligibility is not purely about BMI. Age, existing health conditions, current medicines, and whether you are pregnant, breastfeeding, or planning a pregnancy all affect whether this treatment is appropriate and at what dose. Wegovy is not licensed for use in people under 18. People who are pregnant, breastfeeding, or actively trying to conceive are advised not to use it. Those factors are assessed at consultation, they do not change the weekly schedule itself, but they can change whether you start at all, or whether a dose increase is appropriate at a given review. You can explore the BMI considerations for Wegovy in more depth if that is the part of the picture you are working through.

If you are thinking about the cost side of treatment alongside frequency, the weight-loss treatment overview explains what is included in a private prescription and what the ongoing relationship with your prescriber looks like.

Missing a dose, changing days, and a few questions worth asking your prescriber

Most people have a week at some point where the usual routine breaks. The guidance is to inject the missed dose as soon as you remember, provided the next scheduled dose is at least five days away. If it is closer than that, skip the missed dose entirely and continue on your normal day. The Patient Information Leaflet that comes with your medication is the definitive reference here, not a summary someone else read online.

A few things are worth raising directly with your prescriber rather than managing alone: if side effects are severe enough that you want to stay at a lower dose longer, that is a clinical conversation. If you are considering switching from the weekly injection to the oral semaglutide tablet (which follows a daily rather than weekly schedule) that too requires a review. The broader question of semaglutide frequency across formats is worth reading if you are weighing both routes. And if you are ready to explore starting treatment, speaking to our prescribers is the straightforward next step, the consultation is free and reviewed the same working day by a GPhC-registered pharmacist prescriber, not software.